BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//BioCatalystFeed//bcf//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BioCatalystFeed PRAX catalysts
X-WR-CALDESC:Scheduling/reference data from public records\; dates can move
 . Not investment\, legal or medical advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:9c399b854a9f9d0a9ae1@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:PRAX P3 readout (est.): EMERALD
DESCRIPTION:A Clinical Trial for Participants With DEE to Assess Efficacy\,
  Safety\, Tolerability\, and PK of Relutrigine\nNCT07010471 | PHASE3 | ACT
 IVE_NOT_RECRUITING | sponsor: Praxis Precision Medicines\nPrimary completi
 on date (ESTIMATED)\; top-line results usually follow later.\nDate precisi
 on: month (shown on the first day)\nTicker PRAX (confidence 0.9)\nSource: 
 https://clinicaltrials.gov/study/NCT07010471\nScheduling/reference data fr
 om public records\; dates can move. Not investment\, legal or medical advi
 ce.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07010471
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:227fec5e580455965f52@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:PRAX P3 readout (est.): A Clinical Trial of Elsunersen in Pediatric
  SCN2A-DEE to Assess Efficacy and Safety
DESCRIPTION:A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess
  Efficacy and Safety\nNCT07019922 | PHASE3 | RECRUITING | sponsor: Praxis 
 Precision Medicines\nPrimary completion date (ESTIMATED)\; top-line result
 s usually follow later.\nDate precision: month (shown on the first day)\nT
 icker PRAX (confidence 0.9)\nSource: https://clinicaltrials.gov/study/NCT0
 7019922\nScheduling/reference data from public records\; dates can move. N
 ot investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07019922
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:a6f9a15cda292542a1fb@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:PRAX P3 readout (est.): POWER2
DESCRIPTION:Randomized Clinical Trial Evaluating the Efficacy and Safety of
  Vormatrigine in Adults With Focal Seizures\nNCT07505004 | PHASE3 | ACTIVE
 _NOT_RECRUITING | sponsor: Praxis Precision Medicines\nPrimary completion 
 date (ESTIMATED)\; top-line results usually follow later.\nDate precision:
  month (shown on the first day)\nTicker PRAX (confidence 0.9)\nSource: htt
 ps://clinicaltrials.gov/study/NCT07505004\nScheduling/reference data from 
 public records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07505004
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:1363807714957010cc9c@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261227
DTEND;VALUE=DATE:20261228
SUMMARY:PRAX PDUFA (company-disclosed): ulixacaltamide
DESCRIPTION:PDUFA December 27\, 2026 - Praxis Precision Medicines\, Inc. (u
 lixacaltamide)\nConfidence: company-disclosed\nTicker PRAX (confidence 1.0
 )\nSource: https://www.sec.gov/Archives/edgar/data/1689548/000168954826000
 086/praxisq32026pr.htm\nScheduling/reference data from public records\; da
 tes can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.sec.gov/Archives/edgar/data/1689548/000168954826000086/prax
 isq32026pr.htm
CATEGORIES:pdufa,company-disclosed
END:VEVENT
END:VCALENDAR
